Hector J. Gomez, M.D., Ph. D., the Company's Chairman and Chief Medical Officer. ``We are currently preparing for a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) to discuss the preclinical studies for PT-401.
With all the preliminary preparation for prestudies, how can actual activity not occur within merely a few scant years?